|
US7691598B2
(en)
*
|
2001-03-30 |
2010-04-06 |
Nanoprobes, Inc. |
Method for detecting a target molecule by metal deposition
|
|
US7888060B2
(en)
*
|
2001-03-30 |
2011-02-15 |
Nanoprobes, Inc. |
Method for detecting a target using enzyme directed deposition of elemental metal
|
|
US6670113B2
(en)
*
|
2001-03-30 |
2003-12-30 |
Nanoprobes |
Enzymatic deposition and alteration of metals
|
|
US7892781B2
(en)
*
|
2001-03-30 |
2011-02-22 |
Nanoprobes, Inc. |
Detecting a target using a composite probe comprising a directing agent, a metal nanoparticle and an enzyme
|
|
US6872715B2
(en)
|
2001-08-06 |
2005-03-29 |
Kosan Biosciences, Inc. |
Benzoquinone ansamycins
|
|
WO2003066005A2
(en)
|
2002-02-08 |
2003-08-14 |
Conforma Therapeutics Corporation |
Ansamycins having improved pharmacological and biological properties
|
|
WO2004024141A1
(ja)
*
|
2002-08-29 |
2004-03-25 |
Kyowa Hakko Kogyo Co., Ltd. |
Ｈｓｐ９０ファミリー蛋白質阻害剤
|
|
WO2004057327A1
(en)
*
|
2002-12-20 |
2004-07-08 |
The Registrar, Indian Institute Of Science, |
A novel assay to screen for anti-malarials
|
|
WO2004069999A2
(ja)
*
|
2003-02-04 |
2004-08-19 |
Takeda Pharmaceutical Company Limited |
スクリーニング方法
|
|
US20050020556A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
|
|
US7691838B2
(en)
*
|
2003-05-30 |
2010-04-06 |
Kosan Biosciences Incorporated |
Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
|
|
MXPA06002997A
(es)
|
2003-09-18 |
2007-02-08 |
Conforma Therapeutics Corp |
Novedosos compuestos heterociclicos como inhibidores- hsp90.
|
|
AU2004309395C1
(en)
*
|
2003-12-23 |
2012-10-04 |
Infinity Discovery, Inc. |
Analogs of benzoquinone-containing ansamycins for the treatment of cancer
|
|
US20050267087A1
(en)
*
|
2004-04-28 |
2005-12-01 |
Vassiliki Poulaki |
Inflammatory eye disease
|
|
US7259156B2
(en)
*
|
2004-05-20 |
2007-08-21 |
Kosan Biosciences Incorporated |
Geldanamycin compounds and method of use
|
|
CN101098854B
(zh)
|
2004-07-23 |
2012-12-05 |
恩多塞特公司 |
二价连接体及其轭合物
|
|
KR20070085677A
(ko)
*
|
2004-11-02 |
2007-08-27 |
콘포마 세러퓨틱스 코포레이션 |
만성 림프성 백혈병의 치료 방법 및 치료 조성물
|
|
WO2006052795A2
(en)
*
|
2004-11-05 |
2006-05-18 |
University Of Rochester |
Methods of inhibiting the activity of hsp90 and/or aryl hydrocarbon receptor
|
|
EP1817295B1
(en)
|
2004-11-18 |
2012-11-07 |
Synta Pharmaceuticals Corp. |
Triazole compounds that modulate hsp90 activity
|
|
AU2006230447A1
(en)
|
2005-03-30 |
2006-10-05 |
Conforma Therapeutics Corporation |
Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
|
|
JP5118039B2
(ja)
|
2005-08-18 |
2013-01-16 |
シンタ ファーマシューティカルズ コーポレーション |
Ｈｓｐ９０活性を調節するトリアゾール化合物
|
|
JP5465006B2
(ja)
|
2006-08-11 |
2014-04-09 |
ユニベルシテ・ドウ・ストラスブール |
キナーゼおよびｈｓｐ９０の阻害剤として有用な大環状化合物
|
|
AU2008224988A1
(en)
|
2007-03-14 |
2008-09-18 |
Endocyte, Inc. |
Binding ligand linked drug delivery conjugates of tubulysins
|
|
US9877965B2
(en)
|
2007-06-25 |
2018-01-30 |
Endocyte, Inc. |
Vitamin receptor drug delivery conjugates for treating inflammation
|
|
CN101784565B
(zh)
|
2007-06-25 |
2014-12-10 |
恩多塞特公司 |
含有亲水性间隔区接头的共轭物
|
|
US20110190237A1
(en)
*
|
2008-01-15 |
2011-08-04 |
Nexgenix Pharmaceuticals |
Macrocyclic Prodrug Compounds Useful as Therapeutics
|
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
|
DE102011106984B3
(de)
*
|
2011-07-08 |
2012-10-11 |
Sartorius Stedim Biotech Gmbh |
Microarray-Vorrichtung für das Screenen oder Auffinden von HSP90 Inhibitoren und von Inhibitoren weiterer krankheitsrelevanter Zielstrukturen
|
|
EA201490230A1
(ru)
|
2011-07-08 |
2014-06-30 |
Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч |
Применение меченых ингибиторов hsp90
|
|
US9575056B2
(en)
*
|
2011-07-22 |
2017-02-21 |
Access Bio, Inc. |
Single-pad strip for an improved lateral flow assay and a test device using the same
|
|
GB201116559D0
(en)
|
2011-09-26 |
2011-11-09 |
Univ Leuven Kath |
Novel viral replication inhibitors
|
|
CA2853799A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
|
JP2014534228A
(ja)
|
2011-11-02 |
2014-12-18 |
シンタ ファーマシューティカルズ コーポレーション |
白金含有剤とｈｓｐ９０阻害剤の組合せ療法
|
|
US9402831B2
(en)
|
2011-11-14 |
2016-08-02 |
Synta Pharmaceutical Corp. |
Combination therapy of HSP90 inhibitors with BRAF inhibitors
|
|
US10080805B2
(en)
|
2012-02-24 |
2018-09-25 |
Purdue Research Foundation |
Cholecystokinin B receptor targeting for imaging and therapy
|
|
US20140080175A1
(en)
|
2012-03-29 |
2014-03-20 |
Endocyte, Inc. |
Processes for preparing tubulysin derivatives and conjugates thereof
|
|
US20140079636A1
(en)
*
|
2012-04-16 |
2014-03-20 |
Dinesh U. Chimmanamada |
Targeted therapeutics
|
|
BR112015008365A2
(pt)
|
2012-10-16 |
2017-07-04 |
Endocyte Inc |
composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
|
|
BR112015013431A2
(pt)
|
2012-12-12 |
2017-11-14 |
Vasculox Inc |
anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
EP3738594A1
(en)
|
2013-09-10 |
2020-11-18 |
Madrigal Pharmaceuticals, Inc. |
Targeted therapeutics having an hsp90 ligand as binding moiety
|
|
WO2015066053A2
(en)
|
2013-10-28 |
2015-05-07 |
Synta Pharmaceuticals Corp. |
Targeted therapeutics
|
|
EP3099332A4
(en)
|
2014-01-29 |
2017-06-21 |
Madrigal Pharmaceuticals, Inc. |
Targeted therapeutics
|
|
JP6576942B6
(ja)
|
2014-03-03 |
2019-11-27 |
マドリガル ファーマシューティカルズ インコーポレイテッド |
標的治療薬
|
|
MA39483A
(fr)
|
2014-03-18 |
2015-09-24 |
Synta Pharmaceuticals Corp |
Agents thérapeutiques cibles
|
|
JOP20160086B1
(ar)
|
2015-05-08 |
2021-08-17 |
2 Katholieke Univ Leuven Ku Leuven Research And Development |
مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
|
|
JOP20160198B1
(ar)
|
2015-09-16 |
2022-03-14 |
Janssen Pharmaceuticals Inc |
مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
|
|
JO3633B1
(ar)
|
2015-09-16 |
2020-08-27 |
Katholieke Univ Leuven Ku Leuven Research & Development |
مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
|
|
RU2748401C2
(ru)
|
2015-09-18 |
2021-05-25 |
Арч Онколоджи, Инк. |
Терапевтические антитела к CD47
|
|
BR112018068676A2
(pt)
|
2016-03-31 |
2019-01-15 |
Janssen Pharmaceuticals Inc |
derivados de indol substituídos como inibidores da replicação viral do dengue
|
|
BR112018069601A2
(pt)
|
2016-03-31 |
2019-01-29 |
Janssen Pharmaceuticals Inc |
derivados de indolina substituídos como inibidores da replicação viral da dengue
|
|
JOP20170069B1
(ar)
|
2016-04-01 |
2021-08-17 |
1 Janssen Pharmaceuticals Inc |
مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
|
|
BR112018068956A2
(pt)
|
2016-04-01 |
2019-01-22 |
Janssen Pharmaceuticals Inc |
derivados do composto indol substituídos como inibidores da replicação viral da dengue
|
|
EP3529276A4
(en)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
|
JOP20180025B1
(ar)
|
2017-03-31 |
2021-08-17 |
Janssen Pharmaceuticals Inc |
مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
|
|
JOP20180026A1
(ar)
|
2017-03-31 |
2019-01-30 |
Univ Leuven Kath |
مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
|
|
UA125970C2
(uk)
|
2017-05-22 |
2022-07-20 |
Янссен Фармасьютікалз, Інк. |
Заміщені похідні індоліну як інгібітори реплікації вірусів денге
|
|
EP3630723B1
(en)
|
2017-05-22 |
2022-08-24 |
Janssen Pharmaceuticals, Inc. |
Substituted indoline derivatives as dengue viral replication inhibitors
|
|
KR20200016874A
(ko)
|
2017-06-20 |
2020-02-17 |
마드리갈 파마슈티칼스 인코포레이티드 |
표적화 치료제를 포함하는 병용 요법
|
|
CA3067572A1
(en)
|
2017-06-20 |
2018-12-27 |
Madrigal Pharmaceuticals, Inc. |
Targeted therapeutics
|